Niveau C, Cettour-Cave M, Mouret S, Sosa Cuevas E, Pezet M, Roubinet B
Nat Commun. 2025; 16(1):1083.
PMID: 39870647
PMC: 11772620.
DOI: 10.1038/s41467-025-56392-x.
Warner van Dijk F, Bertram K, ONeil T, Li Y, Buffa D, Harman A
Viruses. 2025; 17(1).
PMID: 39861894
PMC: 11768623.
DOI: 10.3390/v17010105.
Leon B
Trends Immunol. 2025; 46(2):104-120.
PMID: 39843310
PMC: 11835539.
DOI: 10.1016/j.it.2024.12.005.
Glaviano A, Lau H, Carter L, Lee E, Lam H, Okina E
J Hematol Oncol. 2025; 18(1):6.
PMID: 39806516
PMC: 11733683.
DOI: 10.1186/s13045-024-01634-6.
Zeng Y, Huang Y, Tan Q, Peng L, Wang J, Tong F
Mol Med Rep. 2024; 31(2).
PMID: 39670310
PMC: 11650113.
DOI: 10.3892/mmr.2024.13413.
Guidelines for preparation and flow cytometry analysis of human nonlymphoid tissue DC.
Dudziak D, Heger L, Agace W, Bakker J, de Gruijl T, Dress R
Eur J Immunol. 2024; 55(1):e2250325.
PMID: 39668411
PMC: 11739683.
DOI: 10.1002/eji.202250325.
Human CD34-derived plasmacytoid dendritic cells as surrogates for primary pDCs and potential cancer immunotherapy.
Fiore G, Weckwarth W, Paetzold K, Alberti Servera L, Gies M, Rosenhauer J
Front Immunol. 2024; 15:1433119.
PMID: 39575246
PMC: 11578708.
DOI: 10.3389/fimmu.2024.1433119.
Seeing or believing in hyperplexed spatial proteomics via antibodies: New and old biases for an image-based technology.
Bolognesi M, DallOlio L, Maerten A, Borghesi S, Castellani G, Cattoretti G
Biol Imaging. 2024; 4:e10.
PMID: 39464237
PMC: 11503829.
DOI: 10.1017/S2633903X24000138.
The lifespan and kinetics of human dendritic cell subsets and their precursors in health and inflammation.
Lubin R, Patel A, Mackerodt J, Zhang Y, Gvili R, Mulder K
J Exp Med. 2024; 221(11).
PMID: 39417994
PMC: 11488382.
DOI: 10.1084/jem.20220867.
Trial watch: anticancer vaccination with dendritic cells.
Borges F, Laureano R, Vanmeerbeek I, Sprooten J, Demeulenaere O, Govaerts J
Oncoimmunology. 2024; 13(1):2412876.
PMID: 39398476
PMC: 11469433.
DOI: 10.1080/2162402X.2024.2412876.
Therapeutic targets of armored chimeric antigen receptor T cells navigating the tumor microenvironment.
Li X, Chen T, Li X, Zhang H, Li Y, Zhang S
Exp Hematol Oncol. 2024; 13(1):96.
PMID: 39350256
PMC: 11440706.
DOI: 10.1186/s40164-024-00564-w.
Innate immune cells in tumor microenvironment: A new frontier in cancer immunotherapy.
Li C, Yu X, Han X, Lian C, Wang Z, Shao S
iScience. 2024; 27(9):110750.
PMID: 39280627
PMC: 11399700.
DOI: 10.1016/j.isci.2024.110750.
Immune system adaptation during gender-affirming testosterone treatment.
Lakshmikanth T, Consiglio C, Sardh F, Forlin R, Wang J, Tan Z
Nature. 2024; 633(8028):155-164.
PMID: 39232147
PMC: 11374716.
DOI: 10.1038/s41586-024-07789-z.
The current role of dendritic cells in the progression and treatment of colorectal cancer.
Zhang Y, Ji S, Miao G, Du S, Wang H, Yang X
Cancer Biol Med. 2024; 21(9).
PMID: 39177125
PMC: 11414224.
DOI: 10.20892/j.issn.2095-3941.2024.0188.
Extracellular vesicles at the crossroad between cancer progression and immunotherapy: focus on dendritic cells.
Schioppa T, Gaudenzi C, Zucchi G, Pisera A, Vahidi Y, Tiberio L
J Transl Med. 2024; 22(1):691.
PMID: 39075551
PMC: 11288070.
DOI: 10.1186/s12967-024-05457-4.
Plasmacytoid dendritic cells at the forefront of anti-cancer immunity: rewiring strategies for tumor microenvironment remodeling.
Monti M, Ferrari G, Gazzurelli L, Bugatti M, Facchetti F, Vermi W
J Exp Clin Cancer Res. 2024; 43(1):196.
PMID: 39020402
PMC: 11253500.
DOI: 10.1186/s13046-024-03121-9.
Non-Coding RNA in Tumor Cells and Tumor-Associated Myeloid Cells-Function and Therapeutic Potential.
Binder A, Bremm F, Dorrie J, Schaft N
Int J Mol Sci. 2024; 25(13).
PMID: 39000381
PMC: 11242727.
DOI: 10.3390/ijms25137275.
Characterising plasmacytoid and myeloid AXL+ SIGLEC-6+ dendritic cell functions and their interactions with HIV.
Warner van Dijk F, Tong O, ONeil T, Bertram K, Hu K, Baharlou H
PLoS Pathog. 2024; 20(6):e1012351.
PMID: 38924030
PMC: 11233022.
DOI: 10.1371/journal.ppat.1012351.
Dendritic cell subsets and implications for cancer immunotherapy.
Chen M, Zhang F, Goedegebuure S, Gillanders W
Front Immunol. 2024; 15:1393451.
PMID: 38903502
PMC: 11188312.
DOI: 10.3389/fimmu.2024.1393451.
From structural design to delivery: mRNA therapeutics for cancer immunotherapy.
Zhou F, Huang L, Li S, Yang W, Chen F, Cai Z
Exploration (Beijing). 2024; 4(2):20210146.
PMID: 38855617
PMC: 11022630.
DOI: 10.1002/EXP.20210146.